Skip to content

Drug interactions

Aprepitant + Atogepant

Severity: Moderate

Aprepitant and Atogepant: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Atogepant is a CYP3A4 substrate. Aprepitant inhibits CYP3A4 when given as a short course, so atogepant exposure is more likely to increase than decrease, and the legacy direction is doubtful. Higher atogepant levels may increase adverse effects such as nausea, constipation and fatigue.

What this interaction means in plain words

Aprepitant and Atogepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Aprepitant belongs to Gastrointestinal Tract; Atogepant belongs to Central Nervous System.

Evidence level: Low

Why it happens

Aprepitant inhibits CYP3A4, reducing atogepant metabolism, although aprepitant can also induce CYP3A4 with longer exposure.

What to do

Monitor for atogepant adverse effects during aprepitant courses. Consider dose limitation of atogepant in line with labeling for CYP3A4 inhibitors.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Atogepant, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Aprepitant with Atogepant?

MediHelp rates the interaction as moderate. Aprepitant and Atogepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Atogepant is a CYP3A4 substrate. Aprepitant inhibits CYP3A4 when given as a short course, so atogepant exposure is more likely to increase than decrease, and the legacy direction is doubtful. Higher atogepant levels may increase adverse effects such as nausea, constipation and fatigue.

How serious is the interaction between Aprepitant and Atogepant?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for atogepant adverse effects during aprepitant courses. Consider dose limitation of atogepant in line with labeling for CYP3A4 inhibitors.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in